NCT00799331View on ClinicalTrials.gov

Exploratory Study to Assess the Pharmacokinetics of AZD5985

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Healthy
Interventions
DRUG

AZD5985

Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.

DRUG

placebo

Oral suspension.

Trial Locations (1)

Unknown

Research Site, Berlin

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY